ANIXのチャート
ANIXの企業情報
symbol | ANIx |
---|---|
会社名 | Anixa Biosciences Inc (ITUS) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Medical Specialities |
業種 | 事業サポ―トサ―ビス 医療関連(Health Care) |
概要 | 事業概要 アニーシャ・バイオサイエンス(Anixa Biosciences Inc.)(旧名: ITUS Corporation)腫瘍ベースの癌の早期発見用のCchekという診断プラットフォームの開発に従事する。Cchek癌検出プラットフォームは腫瘍の中および周囲に存在し、血流に入る特定の免疫細胞の存在、不存在および量を検出することによって、悪性腫瘍に対する患者の免疫応答を測定する。身体の免疫系とがん細胞を破壊する能力の変更・強化のかわりに、腫瘍発生時に血流に起こる微妙な免疫的変化を測定する技術とプロトコルを開発する。そのプロトコルを通じて、同社は生検で確認された癌患者の末梢血および健康患者の血液と癌患者の血液を区別するバイオマーカーを検出する。 ITUSは米国の特許技術開発・ライセンス企業。特許技術の開発、取得、ライセンス供与に従事する。同社の特許は、携帯電話やモバイル通信の暗号化、電子書籍用電気泳動ディスプレイ「ePaper」、インタ―ネット電話ゲ―トウェイ、ウェブ会議の暗号化、航空会社などによるロイヤルティ―プログラムのポイント転換システムなどを含む。本社はロサンゼルス。 |
本社所在地 | 3150 Almaden Expressway Suite 250 San Jose CA 95118 USA |
代表者氏名 | Amit Kumar アミットクマール |
代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO) |
電話番号 | +1 310-484-5200 |
設立年月日 | 30256 |
市場名 | NASDAQ Small Cap |
ipoyear | ―年 |
従業員数 | 7人 |
url | https://www.anixa.com/ |
nasdaq_url | https://www.nasdaq.com/symbol/anix |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -9.49194 |
終値(lastsale) | 5.29 |
時価総額(marketcap) | 98902612.34 |
時価総額 | 時価総額(百万ドル) 105.07230 |
売上高 | 売上高(百万ドル) 1.11250 |
企業価値(EV) | 企業価値(EV)(百万ドル) 99.73120 |
当期純利益 | 当期純利益(百万ドル) -10.47935 |
決算概要 | 決算概要 BRIEF: For the nine months ended 31 July 2018 Anixa Biosciences Inc revenues increased from $363K to $1.1M. Net loss applicable to common stockholders increased 66% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in R&D increase from $213K to $2.7M (expense). |
ANIXのテクニカル分析
ANIXのニュース
Worldwide Industry for CAR-T Cell Therapy (2021 to 2027) - Players Profiled Include Aleta BioTherapeutics, Anixa Biosciences and BioNTech Among Others 2021/01/07 15:30:00 Benzinga
DUBLIN , Jan. 7, 2021 /PRNewswire/ -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials and Trends, 2021" report has been added to ResearchAndMarkets.com's offering. CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs." T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally.
Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference 2021/01/05 13:30:00 PR Newswire
SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C….
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing 2020/12/14 14:00:00 PR Newswire
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered…
Analyzing The Price Action In Anixa Biosciences Stock Today 2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
Anixa Biosciences to Host Conference Call to Provide Update on Programs 2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference 2021/01/05 13:30:00 PR Newswire
SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C….
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing 2020/12/14 14:00:00 PR Newswire
SAN JOSE, Calif., Dec. 14, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered…
Analyzing The Price Action In Anixa Biosciences Stock Today 2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
Anixa Biosciences to Host Conference Call to Provide Update on Programs 2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
51 Biggest Movers From Yesterday 2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
Analyzing The Price Action In Anixa Biosciences Stock Today 2020/12/10 10:24:00 Benzinga
Anixa Biosciences’s Stock Price And Volume Action Anixa Biosciences’s (NASDAQ: ANIX) stock has been rising Thursday, up 77.85% to a price of …
Anixa Biosciences to Host Conference Call to Provide Update on Programs 2020/10/27 12:00:00 PR Newswire
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m….
51 Biggest Movers From Yesterday 2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference 2020/09/08 12:00:00 PR Newswire
SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual 2020…